📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-05 14:28
5 analysed today
FollowTelegram
5
Today
151,449
All-time analysed
43,382
Positive
6,734
Negative
92,521
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Unjha Formulations Q1 Net Profit Drops 59.7% YoY to ₹15.69 Lacs
Unjha Formulations reported a weak start to FY27, with Q1 revenue declining 9% YoY to ₹3.31 Cr. Net profit saw a significant contraction of 59.7% YoY, falling to ₹15.69 Lacs from ₹38.99 Lacs in the year-ago period. While the company returned to profitability following a ₹74 Lacs loss in the preceding March 2026 quarter, the sharp year-on-year decline in margins is a concern for a micro-cap with a ₹12 Cr market valuation.
Confidence: HIGH
What changedThe company transitioned from a loss-making Q4 FY26 back to profitability in Q1 FY27, but on a significantly lower profit base compared to the previous year.
Why it mattersFor a micro-cap company, high volatility in earnings and a 60% drop in year-on-year profit indicate potential pricing pressure or rising input costs in its pharmaceutical operations.
Q1 Revenue: ₹3.31 CrQ1 Net Profit: ₹15.69 LacsYoY Profit Growth: -59.7%Q1 Revenue vs TTM Revenue: 20.7%Equity Capital: ₹4.48 Cr
📅 Short termThe stock may face downward pressure due to the sharp year-on-year decline in profitability despite the sequential recovery from a loss.
📈 Long termLimited; the company operates at a very small scale with stagnant revenue growth over the last year, making it highly sensitive to minor cost fluctuations.
⚠ Risk flags
- Significant year-on-year margin contraction
- Low promoter holding (36.9%)
- Micro-cap liquidity risks
Key Highlights
Total Income from operations decreased 9% YoY to ₹330.67 Lacs.
Net Profit after tax fell 59.7% YoY to ₹15.69 Lacs compared to ₹38.99 Lacs in June 2025.
Earnings Per Share (EPS) for the quarter stood at ₹0.35, down from ₹0.87 YoY.
The company recovered from a net loss of ₹74 Lacs reported in the previous quarter (March 2026).
Equity Share Capital remains unchanged at ₹448.05 Lacs.
👀 What to Watch
Investors should monitor if the company can restore its quarterly revenue to the ₹4 Cr+ levels seen in late 2025 to regain operating leverage and margin stability.
Unjha Formulations Q1 Results: Net Profit at ₹0.16 Cr, Down 60% YoY; Revenue Declines 9%
Unjha Formulations reported a net profit of ₹15.69 lakhs for Q1 FY27, representing a 59.8% decline from ₹38.99 lakhs in the same quarter last year. Total income fell 9% YoY to ₹3.31 crore, though it showed a marginal recovery from the ₹0.74 crore loss reported in the preceding quarter (Q4 FY26). The company faces significant margin pressure, with raw material costs (₹3.20 crore) accounting for nearly 97% of total income. This micro-cap entity (₹12 Cr market cap) continues to exhibit high volatility in its quarterly bottom line.
Confidence: HIGH
What changedThe company has transitioned back to a marginal profit after a significant loss in Q4 FY26, though it remains well below its performance levels from a year ago.
Why it mattersFor a micro-cap company with a ₹12 crore market valuation, the high sensitivity to raw material prices and declining YoY revenue pose risks to long-term capital preservation.
Net Profit (Q1 FY27): ₹15.69 lakhsTotal Income (Q1 FY27): ₹3.31 croreMaterial Cost to Revenue: 96.7%YoY Revenue Growth: -9.0%Market Cap: ₹12 Cr
📅 Short termThe stock may face pressure due to the sharp YoY decline in profitability and the extremely thin operating margins revealed in this quarter.
📈 Long termLimited; the company's small scale and lack of pricing power over raw materials suggest a challenging structural environment unless revenue scales significantly.
⚠ Risk flags
- High raw material cost concentration
- Micro-cap liquidity risk
- Significant YoY earnings volatility
Key Highlights
Net Profit decreased by 59.8% YoY to ₹15.69 lakhs from ₹38.99 lakhs.
Total Income from operations declined 9% YoY to ₹3.31 crore compared to ₹3.63 crore in Q1 FY26.
Cost of materials consumed stood at ₹3.20 crore, representing 96.7% of total income.
Earnings Per Share (EPS) dropped to ₹0.35 from ₹0.87 in the year-ago period.
The company returned to profit after reporting a net loss of ₹74.28 lakhs in the previous quarter (March 2026).
👀 What to Watch
Investors should monitor the company's ability to manage raw material costs, which currently consume almost the entire revenue base, and watch for any stabilization in quarterly sales volumes.
Unjha Formulations Q1 FY27: Net Profit at ₹0.16 Cr, Recovers from Previous Quarter Loss
Unjha Formulations reported a total income of ₹3.31 Cr for Q1 FY27, representing a 9% decline compared to ₹3.63 Cr in the same quarter last year. The company returned to profitability with a net profit of ₹0.16 Cr, recovering from a significant net loss of ₹0.74 Cr in the preceding March 2026 quarter. Earnings Per Share (EPS) stood at ₹0.35 for the quarter, down from ₹0.87 YoY. The company maintains a debt-free balance sheet but operates at a very small scale with a market capitalization of just ₹12 Cr.
Confidence: HIGH
What changedThe company has transitioned from a loss-making quarter (Q4 FY26) back to a profitable state in Q1 FY27, although revenue remains lower than the previous year's levels.
Why it mattersFor a micro-cap company with limited revenue (₹16 Cr TTM), quarterly profitability is essential to maintain its debt-free status and avoid eroding its small net worth of ₹4 Cr.
Q1 FY27 Revenue: ₹3.31 CrQ1 FY27 Net Profit: ₹0.16 CrYoY Revenue Growth: -9.0%Q1 FY27 EPS: ₹0.35Revenue vs TTM Revenue: 20.6%
📅 Short termThe stock may see neutral to slightly positive sentiment due to the bottom-line recovery, though the lack of top-line growth is a constraint.
📈 Long termLimited structural significance given the small scale of operations and stagnant revenue growth over the past year.
⚠ Risk flags
- Small scale of operations (Micro-cap)
- Low promoter holding (36.9%)
- Year-on-year decline in both revenue and profit
Key Highlights
Total income for Q1 FY27 was ₹3.31 Cr, a slight decrease from ₹3.33 Cr in the previous quarter.
Net profit recovered to ₹15.69 Lakhs (₹0.16 Cr) from a loss of ₹74.28 Lakhs in Q4 FY26.
Total expenses were reduced to ₹3.15 Cr, down from ₹3.82 Cr in the previous quarter, largely due to inventory adjustments.
Cost of materials consumed rose to ₹3.20 Cr in Q1 FY27 compared to ₹2.69 Cr in Q1 FY26.
The company remains a single-segment business with no pending investor complaints as of June 30, 2026.
👀 What to Watch
Investors should monitor if the company can sustain this return to profitability and reverse the year-on-year revenue decline in the coming quarters.
